LONDON - OptiBiotix Health plc, a life sciences company, has announced a key change in its leadership team. Finance Director Graham Myers will step down from the Board on November 30, 2024. David Blain is set to take over as acting Finance Director starting November 1, 2024, with his appointment to the Board pending customary regulatory due diligence.
David Blain is a chartered accountant with the Institute of Chartered Accountants in England and Wales (ICAEW) and brings a wealth of experience to OptiBiotix. He has held financial and board roles in various private and public companies, among them Iksuda Therapeutics Ltd, where he is currently the Financial Director, Applied Graphene Materials plc, Nanoco Group plc, and Inspired Capital plc, previously known as Renovo Group plc.
The transition comes as OptiBiotix prepares for its next growth phase, according to Neil Davidson, the Chairman of OptiBiotix Health plc. Davidson expressed gratitude towards Myers for his contributions over the past year and welcomed Blain to the company.
In addition, the company addressed recent speculation regarding the health of Chief Executive Officer Stephen O'Hara. The company confirmed that O'Hara is on the mend following a brief illness and is expected to return to work soon.
This leadership announcement is based on a press release statement from OptiBiotix Health plc and is intended to provide shareholders and the market with pertinent information regarding these recent developments within the company's executive team.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.